Dr. Hendifar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
West Hollywood, CA 90048Phone+1 310-933-4470Fax+1 310-933-4174
Summary
- Dr. Andrew Hendifar is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, Ronald Reagan UCLA Medical Center, Providence Saint John's Health Center, and Cedars-Sinai Medical Center. He received his medical degree from Tulane University School of Medicine and has been in practice 14 years. He specializes in cancer genetics/cancer risk assessment, gastrointestinal cancer, hematologic oncology, and complementary and integrative and is experienced in pancreatic cancer, amyloidosis, hematologic oncology, neuroendocrine tumors, and myelodysplasia.
Education & Training
- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2007 - 2009
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2003 - 2006
- Tulane University School of MedicineClass of 2003
Certifications & Licensure
- CA State Medical License 2004 - 2026
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Start of enrollment: 2013 Jun 10
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
- Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer Start of enrollment: 2013 Oct 02
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsPonsegromab for the Treatment of Cancer Cachexia.John D Groarke, Jeffrey Crawford, Susie M Collins, Shannon Lubaczewski, Eric J Roeland
The New England Journal of Medicine. 2024-12-19 - A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.Murtaza Ahmed, Brent K Larson, Arsen Osipov, Nilofer Azad, Andrew Hendifar
Oncotarget. 2024-10-11 - Low booster uptake in cancer patients despite health benefits.Jane C Figueiredo, Julia Levy, So Yung Choi, Alexander M Xu, Noah M Merin
Iscience. 2024-09-20
Press Mentions
- Understanding and Treating Pancreatic Cancer CachexiaNovember 14th, 2024
- 3 Innovations That Help Detect Killer Cancers EarlierMay 17th, 2023
- ABVC Provides Oncology Pipeline UpdatesAugust 22nd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: